Quick hello — what brought you here?

• What single event or deadline prompted you to engage inspection readiness support today? Options: Pre-approval inspection linked to filing, Routine surveillance overdue, For-cause inspection or complaint, Post-acquisition due diligence, Other (please describe)
• Which regulator(s) are relevant to the upcoming activity? Options: FDA, EMA, MHRA, Health Canada, PMDA (Japan), WHO, Other
• How soon is the inspection or regulatory milestone you’re preparing for? Options: Within 2 weeks, 2–4 weeks, 1–3 months, 3–6 months, 6+ months, Unknown
• Who will be the primary internal sponsor for this engagement?
• On a scale from 'we feel confident' to 'we're scrambling', how would you describe current internal confidence about being inspection-ready? Options: Confident, Some concerns, Uneasy / need help, We are scrambling

If the inspector walked in tomorrow, what would make them pause?

• Which sample observation would most likely trigger a deep-dive or escalation? Options: Poor documentation control, Repeat deviations without CAPA, Incomplete batch records, Untrained or inconsistent staff interviews, Critical equipment issues, Other (describe)
• Have there been recent events (complaints, recalls, deviations, change controls, mergers) that an inspector would expect you to explain? Tell us which and when.
• Which part of your operation do you suspect is most vulnerable to a regulatory question? Options: Manufacturing operations, Analytical lab, Quality systems/CAPA, Supply chain/sterilization, Clinical records/GCP, Other
• How do you think an inspector will characterize your site culture — collaborative, defensive, or inconsistent? Please give an example that supports your view.
• If we could reduce one inspector concern immediately, which would move the needle most for you (select up to two)? Options: Reduce number of observations, Shorten time to close findings, Improve interview preparedness, Demonstrate system-level CAPA, Secure senior leadership confidence

Where is your process weakest — and why do you think it stays that way?

• Which discrete process areas have routinely produced findings in the past 3 years? Options: Deviation handling, Change control, Training records, Batch documentation, Cleaning/sterilization, Stability/testing, Vendor control, Other
• How long have those weaknesses been present, and what attempts to fix them have already been tried?
• Which of these would describe the root cause pattern you see most often? Options: Procedures exist but aren’t followed, Procedures are unclear or outdated, Resourcing prevents compliance, Systems fragmentation between shifts/sites, Training isn’t reinforced
• Who in the organization has been most frustrated by these gaps—and what have they tried to change?
• If you had to prioritize fixing one process before an inspection, which would it be and why?

Who will be in the hot seat during interviews and access requests?

• Which roles must be available for inspector interviews or witness tasks? Options: Site Director/Plant Manager, Head of Quality/QA, Head of Operations/Manufacturing, Head of Regulatory Affairs, R&D/Clinical Lead, Quality Control Lab Lead, External legal counsel
• Who should we route day-to-day communications through on your side?
• Are there any individuals who should NOT be interviewed without prior approval (e.g., legal, leadership)? Please name or describe.
• Which senior leaders will need regular status updates during the engagement, and how frequently do they want them? Options: Daily, Twice weekly, Weekly, Ad hoc/on escalation, Monthly
• How comfortable are your subject-matter experts with being interviewed by former regulators or external consultant teams? Options: Very comfortable, Somewhat comfortable, Uncomfortable — need coaching, Prefer limited exposure

What counts as success — and what won’t satisfy leadership?

• Which of these outcomes would leadership celebrate as a win from our engagement? Options: No observations/critical 483s, Only minor non-critical observations, Favorable inspector comments on remediation, Accelerated close-out of findings, Maintained production and supply
• Is there an absolute failure threshold we should avoid at all costs (e.g., regulatory hold, warning letter)? Please specify.
• Beyond inspection results, what secondary benefits would make this engagement high value (e.g., stronger SOPs, better training, audit-ready evidence packages)? Options: Improved SOPs, Robust evidence packages, Stronger interview capability, Faster remediation planning, Cross-site consistency
• How will you measure return on investment for this work? What KPIs or timelines matter most?
• Who will sign off that our scope was successful—title or name—and what explicit acceptance criteria will they use?

Timeline reality check — what’s actually on the calendar?

• If leadership expects a clean inspection in X weeks, what does 'clean' mean to them and is that expectation realistic? Options: No findings, Only minor observations, No critical systemic issues, Unsure / leadership hasn't defined it
• Are there planned production, shutdown, or validation windows that limit when we can be on-site? Options: Ongoing production (no windows), Planned shutdown/maintenance coming, Validation runs scheduled, Flexible access
• How many working weeks can your core SMEs reasonably commit to interviews and remediation activities? Options: Less than 1 week, 1–2 weeks, 3–4 weeks, 4+ weeks
• Are there regulatory filing dates or submission targets that constrain our schedule? Options: Yes—specific filing date, Tentative filing window, No filing constraints, Not disclosed
• If we recommended a 6–8 week prep plan but you had only 2–3, what trade-offs would you accept? Options: Reduce scope to critical modules, Increase consultant intensity (longer days), Delay non-critical activities, Accept higher inspection risk

Site logistics — what will make day one smooth or chaotic?

• Which document transfer methods are available and preferred for secure file review? Options: Secure SFTP, Encrypted SharePoint, VDR (virtual data room), Secure email, On-site review only
• Will consultants have network access for electronic records, LIMS, or QMS tools, or will access be read-only/mediated? Options: Full remote access, Read-only access, On-site mediated access, No electronic access
• What site badge, PPE, or safety trainings must consultants complete before entering manufacturing areas?
• Are there sensitive areas or documentation that require additional approvals or escorts? Please list.
• Do you prefer mock inspections to be onsite, remote, or hybrid, and why? Options: Onsite, Remote, Hybrid

Roles, responsibilities, and escalation — who owns what?

• Do you have an internal RACI or decision matrix we should align to, or should we propose one for sign-off? Options: Internal RACI exists, No RACI — please propose, Partial RACI — needs update
• Who will be the final approver for remediation plans and evidence packages?
• If we identify a critical finding during a mock inspection, what is your preferred escalation path? Options: Notify Site Leader immediately, Notify Head of Quality and Regulatory, Activate incident response team, Handle within project team then escalate
• Which internal groups must be looped into weekly status updates (select all that apply)? Options: Quality Assurance, Operations/Manufacturing, Regulatory Affairs, Legal/Compliance, Supply Chain, Executive Leadership
• Are there external stakeholders (parent company, acquirer, CROs) who require visibility or approval during the engagement? Options: Yes — parent/acquirer, Yes — CRO/CMO partners, No external stakeholders, Unsure

The honest fears you might not say out loud

• What consequence would keep you up at night if it resulted from this inspection (select up to two)? Options: Regulatory hold or stop distribution, Warning letter or public enforcement, Supply interruption, Loss of customer trust, Financial penalties
• Have you shared these concerns with leadership? If not, what has stopped you from raising them?
• How much organizational tolerance is there for short-term disruption in order to materially reduce inspection risk? Options: High tolerance (major changes allowed), Moderate tolerance (targeted disruptions), Low tolerance (minimal disruption), Unknown
• If an inspector found systemic issues, what internal political or business constraints would make remediation difficult?
• What's the worst-case scenario you imagine for this inspection—and what would you need from a consultant to face it confidently?

If we had your go‑ahead today, what would let us start tomorrow?

• Which immediate administrative items must be completed before work starts (e.g., NDA, PO, site access requests)? Options: Signed NDA, Purchase order/contract, Site access approvals, Background checks/badges, Other
• Who needs to attend an initial 60-minute kickoff and what decision authority should they hold?
• Would you prefer a prioritized 'critical path' scope that guarantees the highest-risk mitigation within a compressed timeline? Options: Yes—prioritized critical path, No—full scope only, Open to consultant recommendation
• Are there budget constraints or approval steps that could delay start, and if so, what are they?
• What would be a meaningful first deliverable in week one that demonstrates momentum to your leadership? Options: Executive risk brief, Mock-interview readiness checklist, Top 5 ranked process gaps, Immediate quick-win remediation plan

• Current-State & Consequence Alignment
• Inspection Scenario Design Workshop
• Mock Inspection Run-Through (Tabletop & Role-Play)
• Back-Room Support Demonstration & Close-Out Acceleration
• Validation & Acceptance — Sign-off on Scenarios and Execution Plan

• Secure commitment to adopt the evidence templates and remediation workflow during Deployment Enablement.
• Gain stakeholder confirmation that scenarios accurately reflect site risk and inspector behavior.
• Consulting team to draft detailed scenario scripts (questions, documents, expected inspector probes) for top 4 scenarios.
• Site SMEs to gather exemplar documents and artifacts referenced in each scenario (30 calendar days of batch records, training logs, change control examples).
• Assign scenario owners who will participate in mock inspections and lead remediation for each scenario.
• Setup: Roles, rules, and success signals
• Validate that mock inspections reveal the same findings as expected scenarios and that back-room support reduces time-to-evidence and mitigates escalation.
• Produce a prioritized observation log with owners and estimated close-out timelines when backed by consultant support.
• Confirm any adjustments required to playbooks or scenario scripts before live mock/onsite runs.
• Finalize the observation log from the run-through with owners and 48-hour quick-response SLAs for critical items.
• Consulting team to prepare a back-room response template and evidence bundle sample for each observation type.
• Schedule the onsite/live mock inspection and assign participants with calendar invites.
• Recap metrics and goal (future-state)
• Prove that back-room support and playbooks materially reduce findings and shorten close-out timelines with a concrete example.
• Agree SLAs, escalation paths, and playbook acceptance criteria for live inspection support.
• Introductions & Goals
• Consultant to deliver evidence package templates and remediation playbook within 48 hours.
• Site to map internal contacts to SLA responsibilities and confirm escalation contacts.
• Legal/regulatory liaison to review and approve any messaging templates used during live advisory.
• One-line recaps: current-state, consequence, future-state
• Obtain stakeholder sign-off that scenarios and remediation approach are accurate and sufficient to achieve the future-state.
• Finalize execution plan, owners, and timeline for the Deployment group activities.
• Ensure commercial/procurement alignment if scope or staffing adjustments are required.
• Documented sign-off on scenarios and execution plan to be uploaded to the shared project workspace.
• Schedule the first Deployment Enablement milestone (Pre-Deployment Readiness checkpoint) and assign meeting owners.
• Procurement/commercial to confirm final statement-of-work or PO requirements if scope changed.
• Produce and validate a single-sentence current-state that all stakeholders accept.
• Explicitly quantify inspection consequences in operational and financial terms.
• Agree a one-sentence future-state outcome to prove via scenarios.
• Identify named owners and missing artifacts required for scenario construction.
• Site to deliver any missing documents (SOPs, CAPAs, inspection history) within 3 business days.
• Regulatory lead to provide inspection-critical processes and stakeholder contact list.
• Consulting lead to draft and circulate the confirmed one-sentence current-state and future-state.
• Recap: Current-state, consequence, future-state
• Produce a prioritized list of realistic inspection scenarios with associated likely findings.
• Map each scenario to explicit remediation levers and expected impact on consequence metrics.
• Pre-work verification
• Run Scenario A (tabletop with live Q&A)
• Identify high-risk processes and failure modes
• Proof summary from run-throughs
• Demonstrate evidence package construction
• Validation checks with stakeholders
• Current-state one-sentence
• Live advisory simulation
• Create realistic inspection scenarios
• Debrief Scenario A
• Run Scenario B (document-focused probe)
• Remediation planning & rapid execution workflow
• Finalize scope, deliverables, and timelines
• Map findings to consequence and remediation levers
• Consequence quantification
• Debrief Scenario B and consolidate observation log
• Prioritize scenarios for mock inspections
• Future-state one-sentence
• KPI model: expected impact
• Sign-off and next steps
• Critical-process & stakeholder validation
• Close: Lessons, immediate remediation steps, and validation check
• Validation checkpoint
• Agreement on SLAs and escalation path

• Onsite inspector-style mock inspection (full-day)
• Staff interview simulations and inspector role-play
• Live back-room advisory during active inspection
• Assemble inspection-ready core document binder
• Prepare FDA 483 / EMA observation response drafts
• Execute CAPA remediation and SOP revisions
• Sanitize and reconstruct batch records for inspection
• Establish inspection evidence room and document controls
• Deliver GMP inspection training for site personnel
• Mock product/sample retrieval and chain-of-custody demo
• Remediate laboratory data integrity issues and evidence
• Compile pre-approval submission crosswalk evidence binder

Onsite inspector-style mock inspection (full-day)

• Which regulatory authority scenario should the mock inspection emulate? Options: FDA (US), EMA (EU), MHRA (UK), Other / Multi-authority
• Which site areas should be included in the full-day mock inspection (list departments/lines)?
• Do you want a single full-day mock inspection or multiple shorter, focused mock inspections? Options: Single full-day, Two half-days, Multiple targeted sessions
• What is the current cadence of internal audits and prior mock inspections at this site? Options: None in past 2+ years, Occasional (annual or less), Regular (quarterly/monthly)
• Are there known high-risk processes or recent events you want the mock inspection to stress-test (e.g., aseptic fill, IV compounding, complaints)?
• What are your primary success criteria for the mock inspection (e.g., number of findings, staff confidence, playbook validation)? Options: Minimize findings, Validate response playbook, Improve interview readiness, Identify systemic gaps, Other

Staff interview simulations and inspector role-play

• Which roles should participate in interview simulations (e.g., QA head, site director, operators)?
• Do you prefer scripted inspector questions, adaptive inspector probing, or a mix? Options: Scripted (standardized), Adaptive (investigator-style), Mixed approach
• How long should individual interview simulations run (typical duration per participant)? Options: 15-30 minutes, 30-60 minutes, 60+ minutes
• Would you like immediate feedback/debrief after each simulation or a consolidated team debrief? Options: Immediate feedback, Consolidated debrief, Both
• Are there specific messaging or organizational constraints interviewees should be coached on (e.g., acquisitions, product holds)?
• Do you need role-play artifacts (recordings, transcripts, coaching notes)? Options: Yes, No

Live back-room advisory during active inspection

• Will you have an on-site war room for back-room support or will advisory be remote? Options: On-site war room, Remote support, Hybrid
• What level of back-room support is required (real-time messaging, live document drafting, executive briefings)? Options: Real-time messaging, Live document drafting, Executive briefing support, All of the above
• Which hours/days do you expect the advisory team to be available during the inspection window? Options: Standard business hours, Extended hours, 24/7 coverage
• Who will be the primary on-site point(s) of contact for receiving advisory recommendations?
• Do you have existing playbooks or SOPs for inspection escalation we should align with? Options: Yes, existing playbooks, Partial/fragmented, No, need us to draft
• Are there confidentiality or legal constraints for communications during the live inspection (e.g., counsel involvement)? Options: Yes, No

Assemble inspection-ready core document binder

• Which core document sets must be included (choose all that apply)? Options: Quality Manual & QMS maps, Batch records, SOPs & controlled documents, Stability and analytical reports, Change control records, Validation summaries
• Do you require hard-copy binders, a digital evidence room, or both? Options: Hard-copy binders, Digital evidence room, Both
• What target turnaround time is acceptable for assembling the core binder? Options: 1 week, 2 weeks, 3-4 weeks, Other
• Who will own final approvals for the binder contents (role or person)?
• Are there controlled documents that currently lack revision history or approvals we should prioritize? Options: Yes, No, Unsure — need review
• Do you want cross-referenced index and inspector quick-guide summaries included? Options: Yes, No

Prepare FDA 483 / EMA observation response drafts

• Do you anticipate responses will be submitted by the site, corporate/regulatory affairs, or with consultant drafting support? Options: Site-led, Corporate/regulatory-led, Consultant-drafted with site review
• What level of detail do you require in response drafts (brief corrective note vs detailed CAPA and evidence crosswalk)? Options: Brief corrective note, Detailed CAPA with evidence crosswalk, Full root-cause analysis and timeline
• Are there pre-existing CAPAs or response templates the draft should align to? Options: Yes - provide templates, No - create new templates, Partial
• What timeline do you have from observation receipt to intended response submission? Options: 72 hours, 15 days, 30 days, Other
• Who is responsible for implementing and owning the CAPA referenced in responses?
• Do you want us to include measurable acceptance criteria and verification steps in the response drafts? Options: Yes, No

Execute CAPA remediation and SOP revisions

• Will remediation tasks be executed by site resources, corporate teams, or do you want consultant-managed execution? Options: Site resources, Corporate teams, Consultant-managed, Hybrid
• How many open CAPAs or SOP revisions are in scope for execution? Options: 1-5, 6-15, 16-30, 30+
• Do CAPAs require cross-functional workshops (e.g., QA, manufacturing, R&D, supply chain)? Options: Yes, No
• What is the expected timeline for completing highest-priority remediation items? Options: 2 weeks, 4 weeks, 8-12 weeks, Custom
• Do SOP revisions require formal training and retraining records that must be produced for inspectors? Options: Yes, No, Some do
• Are there resource constraints (e.g., subject matter experts availability) that could impact remediation execution? Options: Yes, No

Sanitize and reconstruct batch records for inspection

• How many batch records require sanitization or reconstruction? Options: 1-5, 6-20, 21-50, 50+
• Are batch records paper-based, electronic, or mixed? Options: Paper, Electronic, Mixed
• Do reconstructed records require gap annotation (what changed and why) for audit trail purposes? Options: Yes, No
• What is the priority ranking of batches (e.g., pre-approval lots, recent commercial lots)?
• Will internal QA/legal review be required before reconstructed records are shared with inspectors? Options: Yes, No, Conditional
• Are there data integrity concerns or missing signatures that drive the need for reconstruction? Options: Yes, No, Unknown - need assessment

Establish inspection evidence room and document controls

• Do you have a preferred platform for a digital evidence room (e.g., secure cloud, VDR) or require consultant recommendation? Options: Client platform, Recommend secure cloud/VDR, No preference - need recommendation
• Which document control features are mandatory (versioning, audit trail, access logs, watermarking)? Options: Versioning, Audit trail, Access logs, Watermarking, All of the above
• Who should have viewer vs editor access to the evidence room?
• Do you require signed attestations or chain-of-custody logs for evidence transferred to the room? Options: Yes, No, Only for specific documents
• What retention and export controls are required after the inspection concludes? Options: 30 days, 90 days, Return & purge on request, Custom policy
• Are there bandwidth or IT security constraints for on-site uploads that we should plan for? Options: Yes, No

Deliver GMP inspection training for site personnel

• Which cohorts need training (operators, supervisors, QA, management)? Options: Operators, Supervisors, QA, Senior Management, All
• Preferred training format? Options: Live instructor-led, Virtual instructor-led, Recorded modules, Blended
• How long should training sessions be (per cohort)? Options: 30-60 minutes, 1-2 hours, Half-day, Full-day
• Do you require assessment (quizzes/certification) and training records exported to LMS? Options: Yes, No
• Are there site-specific SOPs or topics to emphasize (e.g., aseptic gowning, deviation handling)?
• Would you like role-based playbooks or quick-reference inspection guides created? Options: Yes, No

Mock product/sample retrieval and chain-of-custody demo

• Which sample types should be included (stability samples, retained samples, QC samples)? Options: Stability, Retained, QC, Archive, Other
• Are samples currently stored on-site or at third-party labs/storage? Options: On-site, Third-party lab, Mixed
• Do you have existing chain-of-custody forms/procedures or need standard templates? Options: Existing forms, Need templates, Partial
• Should the demo include physical retrieval, documentation handover, and transport simulation? Options: Yes - full demo, Documentation only, Physical retrieval only
• Are there temperature-controlled or controlled-substance handling requirements to test? Options: Yes, No
• Is witness evidence (photos, time-stamped logs) required as part of the demo deliverable? Options: Yes, No

• Statement of Work (SOW)
• Master Services Agreement (MSA)
• Pricing & Payment Schedule
• Access Windows & Site Logistics Agreement
• Client & Consultant Responsibilities (RACI)
• Acceptance Criteria & Success Signals
• Escalation & Governance Plan
• Data Security & Privacy / DPA
• Change Control & Scope Amendment
• Insurance, Indemnity & Liability
• Third‑Party Subcontractor Consent
• Kickoff Authorization / Start Order

• Inspection Outcomes Review
• Lessons Learned & Root Cause Workshop
• Open Issues Triage & Remediation Planning
• Regulatory Closure & External Communication
• Continuous Improvement & Next-Inspection Readiness

• Draft the regulatory response(s) and circulate for Quality and Legal review within the agreed timeline.
• Prepare templates for evidence packages and verification checklists for each CAPA.
• Schedule follow-up RCA validation sessions for complex/systemic items.
• Inventory of Open Issues
• Convert every open observation into a tracked remediation entry with owner and timeline.
• Prioritize remediation work by regulatory and patient risk to focus resources.
• Agree escalation criteria and monitoring cadence to ensure timely closure.
• Populate the issue tracker with prioritized entries, owners, milestones, and risk score.
• Assign evidence package leads and set deadlines for first deliverables.
• Establish weekly remediation review meetings and circulate invite and agenda.
• Define owners for drafting, compiling, and approving submission packages.
• Determine Need for Regulatory Notifications/Responses
• Agree which inspection items require formal regulatory response and the timelines for submission.
• Align on external communication messaging and stakeholder notification schedule.
• Welcome & Objectives
• Compile and validate the submission evidence package and obtain required sign-offs.
• Prepare stakeholder communication templates and schedule distribution dates.
• Summary of Lessons Learned & Improvement Backlog
• Handover ownership of ongoing issues and improvements to internal process owners with clear governance.
• Establish a shared channel for transparent, auditable tracking of open items and enhancements.
• Schedule and resource next inspection readiness activities including mock inspections and refresher training.
• Define KPIs and dashboard metrics to monitor sustained compliance and remediation effectiveness.
• Create the shared channel (e.g., collaborative workspace) and publish governance rules, access list, and owner contacts.
• Draft the improvement implementation plan including SOP updates, training schedule, and owners.
• Build the readiness dashboard and populate initial KPIs; schedule monthly review meetings.
• Confirm a single, agreed factual record of inspection outcomes and evidence.
• Determine which success signals were met and which require remediation or follow-up.
• Assign immediate owners and timelines for any critical open items.
• Agree on cadence and format for ongoing status updates.
• Finalize and circulate the Inspection Outcomes Report (including evidence index) within 48 hours.
• Tag and escalate any critical findings that threaten regulatory timelines to executive sponsors.
• Schedule the Triage & Remediation Planning meeting and invite named owners.
• Recap of Outcomes & Scope for Workshop
• Create a prioritized CAPA list tied to documented root causes.
• Define clear acceptance criteria and evidence needed to close each CAPA.
• Assign accountable owners and realistic timelines for remediation tasks.
• Identify quick wins that reduce regulatory risk immediately.
• Publish the CAPA register with root cause statements, owners, due dates, and acceptance criteria.
• Risk-Based Prioritization
• RCA Methodology & Roles
• Review Success Signals & Acceptance Criteria
• Draft Response Content & Evidence Package Plan
• Shared Channel Governance & Roles
• SOP/Training Update Plan
• Inspection Findings Summary
• Breakout RCA Sessions by Process Area
• Remediation Plan per Item
• Internal Approvals & Sign-off Workflow
• Monitoring KPIs & Dashboard Approach
• Map Findings to Success Signals
• Resource & Responsibility Gaps
• Synthesize Findings — Systemic vs Isolated
• External Stakeholder Communication Plan
• Next-Inspection Roadmap & Mock Inspection Schedule
• Submission Timing & Contingency
• Define CAPA Proposals & Success Metrics
• Quantitative Metrics & Risk Implication
• Escalation Paths & Decision Points
• Clarifications & Fact Checks
• Monitoring & Reporting Cadence